Science and Technology Resources

OSTR正在通过弗雷德里克国家实验室(FNL)的蛋白质表征实验室为CCR研究人员支持哺乳动物细胞中的一些蛋白质表征分析。OSTR继续评估所有可用于蛋白质和基因表达谱分析和其他高通量技术的商业平台。为了使CCR研究人员容易地获得最新进展，OSTR与提供基因组和新陈代谢图谱技术和服务的公司建立了一些安排。这些协议大大降低了成本，并为CCR调查人员提供了一种高效而简单的方式来获取这些技术。已经建立了一项补贴计划，为CCR研究人员获得先进的基因组、蛋白质组、代谢组和生物信息技术提供补贴。这一资助机制帮助延长了CCR实验室可用的有限研究资金，并允许我们的研究人员进行原本可能成本高昂的实验。许多受资助的项目都在顶级期刊上发表了重要文章。最近，OSTR参与了CCR获取下一代测序技术的努力，包括建立一个新的单细胞分析设施，现在位于41号楼，任何CCR调查员都可以使用。为了应对CCR迅速增长的管理和分析大量基因组和蛋白质组数据的需求，OSTR与生物信息学公司建立了几个合作伙伴关系。在为NCI节省大量成本的情况下，OSTR代表NCI的所有研究人员谈判了各种许可协议，以普遍获得用于微阵列实验、蛋白质组图谱研究和基因组分析(包括下一代测序数据)的生物信息学和统计分析的尖端工具。此外，OSTR还向所有NCI提供了一些用于研究通路和生物关联网络的软件应用程序。OSTR继续评估CCR在生物信息学和生物统计领域的要求。我们将继续与Leidos Biomedical Research(LBR)合作，创建CCR专用生物信息学计划，为CCR调查人员提供支持。通过这一位于贝塞斯达园区的新计划，可以对高通量基因组和蛋白质组数据的分析提供支持。最近，OSTR承担了合作蛋白质技术资源的纳米蛋白质组学部分的管理工作。这一核心对所有CCR研究人员开放，致力于开发和实施基于蛋白质的尖端技术，以促进CCR/NCI/NIH的发现、翻译和临床研究。该核心提供专业知识和最先进的技术，以满足CCR/NCI/NIH研究人员在以下方面的需求：快速和精确的蛋白质分析；全面和定量的细胞信号事件剖析；纳米级定量蛋白质组学评估；生物标记物开发和治疗目标识别；以及临床适用的分析开发和应用。最近，CPTR正在向CCR社区提供空间蛋白质组学和转录组学。此核心单独报告。

The OSTR is supporting a number of protein characterization analyses in mammalian cells for CCR investigators through the Laboratory of Protein Characterization at the Frederick National Lab (FNL). The OSTR continues to evaluate all commercially available platforms for protein and gene expression profiling and other high throughput technologies. To make the latest advances easily accessible to CCR researchers, the OSTR has established a number of arrangements with companies providing genomic and metabolomic profiling technologies and services. These agreements have led to far lower cost and an efficient and easy way for CCR investigators to access these technologies. A subsidy program has been established providing subsidies to support CCR investigator access to advanced genomic, proteomic, metabolomic, and bioinformatic technologies. This funding mechanism has helped to extend the limited research dollars available to CCR laboratories and has permitted our researchers to conduct experiments that might otherwise be cost prohibitive. Many of the funded projects have led to important publications in top-tier journals. Most recently, the OSTR has been involved in CCR's efforts to access the next generation sequencing technologies, including the setting up of a new single cell analysis facility now located building 41, which is available to any CCR investigator. In response to CCR's rapidly growing need to manage and analyze large sets of genomic and proteomic data, the OSTR has developed several partnerships with bioinformatics companies. At significant cost savings to NCI, OSTR negotiated a variety of license agreements on behalf of all NCI researchers for universal access to sophisticated tools for bioinformatic and statistical analysis of microarray experiments, proteomic profiling studies, and genomic analysis including next-generation sequencing data. In addition, the OSTR has made a number of software applications for the investigation of pathways and biological association networks available to all of NCI. The OSTR continues to assess CCR's requirements in the area of bioinformatics and biostatistics. We continue to work with Leidos Biomedical Research (LBR) to create a CCR dedicated Bioinformatics Program to provide support to CCR investigators. Support for analysis of high throughput genomic and proteomic data is being made available through this new program, which is located on the Bethesda campus. Most recently, the OSTR has taken on the management of the NanoScale Proteomics section of the Collaborative Protein Technology Resource. This Core is an open to all CCR investigators and dedicated to developing and implementing cutting-edge protein-based technologies to facilitate discovery, translational and clinical research in CCR/NCI/NIH. This Core offers expertise and provides state-of-the-art technologies to accommodate the demands of CCR/NCI/NIH investigators for: Rapid and precise protein analysis; Comprehensive and quantitative cell signaling event dissection; Nanoscale quantitative proteomics assessment; Biomarker development and therapeutic target identification; and, Clinical applicable assay development and applications. Most recently, the CPTR is offering spatial proteomics and transcriptomics to the CCR community. This Core is reported separately.